<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02625376</url>
  </required_header>
  <id_info>
    <org_study_id>AGED/EudraCT : 2015-001577-41</org_study_id>
    <nct_id>NCT02625376</nct_id>
  </id_info>
  <brief_title>Resveratrol for Exudative Age-Related Macular Degeneration</brief_title>
  <acronym>AGED</acronym>
  <official_title>Influence of Resveratrol and Resvega Versus Placebo on Incidence of Bilateralisation of Exudative AMD: a Double Masked Prospective Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an interventional, prospective, randomized, comparative monocentric study aiming to
      evaluate the safety and efficacy of Resveratrol to reduce the progression of exudative
      Age-Related Macular Degeneration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interventional, prospective, randomized, comparative monocentric study aiming to evaluate the
      safety and efficacy of Resveratrol to reduce the progression of exudative Age-Related Macular
      Degeneration.

      Comparison of incidence of choroidal neaovascularization between each study group will be
      performed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparaison of incidence of choroidal neovascularization between resveratrol group and placebo group at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>What is the influence of the daily intake of 500 mg of resveratrol on the incidence of neovascularization of the second eye?</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparaison of incidence of choroidal neovascularization between Resvega group and placebo group at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>What is the influence of the daily intake resvega on the incidence of neovascularization of the second eye?</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">489</enrollment>
  <condition>AMD</condition>
  <condition>Age-related Macular Degeneration</condition>
  <condition>Choroidal Neovascularisation</condition>
  <arm_group>
    <arm_group_label>Trans-Resveratrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capsule of 250 mg of resveratrol. two capsules daily : one in the morning and evening for 24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resvega</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>capsule composed of antioxydant, omega 3, carotenoid, 15 mg of resveratrol, zinc and copper.
two capsules daily : one in the morning and evening for 24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>capsule of medium chain triglyceride. two capsules daily : one in the morning and evening for 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Resvega</intervention_name>
    <description>Dietary supplementation with Resvega BD</description>
    <arm_group_label>Resvega</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Trans-Resveratrol</intervention_name>
    <description>Dietary supplementation with resveratrol 250 mg BD</description>
    <arm_group_label>Trans-Resveratrol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Dietary supplementation with a placebo BD</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women aged 55 or more with unilateral exudative AMD

          -  Visual acuity less or equal to 20/25 in the most affected eye

        Exclusion Criteria:

          -  Allergy to an investigational product

          -  atrophic Age-Related Macular Degeneration or age related maculopathy

          -  significant media opacities

          -  Other retinal pathology (diabetic retinopathy, high myopia, retinal dystrophy)

          -  Recent Cataract surgery

          -  Previous history of vitrectomy

          -  Acute or chronic severe organ failure

          -  Present participation in other clinical research study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas LEVEZIEL, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dpt of Ophthalmology, University Hospital of Poitiers, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas LEVEZIEL, MD, PhD</last_name>
    <phone>+33 (0)5.49.44.41.82</phone>
    <email>nicolas.leveziel@chu-poitiers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Poitiers - Ophtalmology</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas leveziel, MD</last_name>
      <email>nicolas.leveziel@chu-poitiers.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2015</study_first_submitted>
  <study_first_submitted_qc>December 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2015</study_first_posted>
  <last_update_submitted>May 23, 2016</last_update_submitted>
  <last_update_submitted_qc>May 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

